Ryan Polli

Company: Novartis AG

Job title: Senior Principal Scientist, PK Sciences

Seminars:

Impact of Antibody Fc Engineering on Translational Pharmacology & Safety: Insights From Industry Case Studies 10:30 am

Balancing Efficacy and Safety through Fc Engineering: • Fc engineering significantly alters antibody interactions with FcγRs and C1q, enabling enhancement or silencing of ADCC, ADCP, and CDC. These modifications, however, may also lead to undesired effects, such as inappropriate immune activation, cytokine release, platelet activation, and increased risk of thrombotic events. Hence, careful assessment of…Read more

day: Conference Day One